Evidence map›Paper›PMID 24337465›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2014

Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance.

Irina Lonskaya, Michaeline L Hebron, Nicole M Desforges, Joel B Schachter, Charbel E-H Moussa

Registry-linked trialAbstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02921477 (Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias), which is not on this map. Cited by 90 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02921477 phase1unknown statusnot on this mapstarted 2016, after this paper: background citation

Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias

TypeinterventionalSponsorNeurological Associates of West Los AngelesRan2016 to 2025Enrolled150ConditionsMild Cognitive Impairment, DementiaArmsbosutinib
3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 1 synthesis or guideline pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. RawNutrition research and practice · 2023
    Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Irina LonskayaDepartment of Neuroscience, Laboratory for Dementia and Parkinsonism, Georgetown University Medical Center, 3970 Reservoir Rd, NW, TRB, Room WP26B, Washington, DC, 20057, USA.
Michaeline L Hebron
Nicole M Desforges
Joel B Schachter
Charbel E-H Moussa
Georgetown University · USGeorgetown University Medical Center · USUnited States Military Academy · US

Funding

Parkin protection in gene transfer animal models (KO-1 Award)K01AG030378 · NIA · GEORGETOWN UNIVERSITY · PI MOUSSA, CHARBEL · 2008 to 2012
$607k
NIA NIH HHS K01 AG030378PHS HHS 30378
6 · The paper itself

Abstract

unlabelledAlzheimer's disease (AD) is a neurodegenerative disorder associated with amyloid accumulation and autophagic changes. Parkin is an E3 ubiquitin ligase involved in proteasomal and autophagic clearance. We previously demonstrated decreased parkin solubility and interaction with the key autophagy enzyme beclin-1 in AD, but tyrosine kinase inhibition restored parkin-beclin-1 interaction. In the current studies, we determined the mechanisms of nilotinib-induced parkin-beclin-1 interaction, which leads to amyloid clearance. Nilotinib increased endogenous parkin levels and ubiquitination, which may enhance parkin recycling via the proteasome, leading to increased activity and interaction with beclin-1. Parkin solubility was decreased and autophagy was altered in amyloid expressing mice, suggesting that amyloid stress affects parkin stability, leading to failure of protein clearance via the lysosome. Isolation of autophagic vacuoles revealed amyloid and parkin accumulation in autophagic compartments but nilotinib decreased insoluble parkin levels and facilitated amyloid deposition into lysosomes in wild type, but not parkin(-/-) mice, further underscoring an essential role for endogenous parkin in amyloid clearance. These results suggest that nilotinib boosts the autophagic machinery, leading to increased level of endogenous parkin that undergoes ubiquitination and interacts with beclin-1 to facilitate amyloid clearance. These data suggest that nilotinib-mediated autophagic changes may trigger parkin response via increased protein levels, providing a therapeutic strategy to reduce Aβ and Tau in AD. KEY MESSAGE: Parkin solubility (stability) is decreased in AD and APP transgenic mice. Nilotinib-induced autophagic changes increase endogenous parkin level. Increased parkin level leads to ubiquitination and proteasomal recycling. Re-cycling decreases insoluble parkin and increases parkin-beclin-1 interaction. Beclin-1-parkin interaction enhances amyloid clearance.

Indexed as

Alzheimer DiseaseAmyloidAnimalsAutophagyCell Line, TumorEnzyme StabilityHippocampusHumansMaleMice, Inbred C57BLMice, TransgenicProtein Kinase InhibitorsPyrimidinesRatsUbiquitinationUbiquitin-Protein LigasesAmyloidnilotinibparkin proteinProtein Kinase InhibitorsPyrimidinesUbiquitin-Protein Ligases

Identifiers

PMID24337465
PMCPMC3975659
OpenAlexW2015808257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.